The global mononucleosis diagnostic market is expected to witness an incremental growth over the forecast period due to increasing prevalence in mononucleosis epidemics globally and the adoption of advanced diagnostic facilities. Mononucleosis is a communicable disease caused by the Epstein Barr Virus, characterized by sore throat, fatigue, and fever. Additionally, increasing health awareness and knowledge amongst patients, the collateral effect of other disease epidemics having similar symptoms such as AIDS, strep throat, Lyme disease, etc. are also expected to boost the market growth in the coming seven years. Similarly, adoption of sophisticated technology such as chemiluminescence technology, chromatographic immunoassay, immuno-latex test, Reverse Transcription Polymerase Chain Reaction test(RT-PCR), DNA probes, solid-phase immunoassay facilitating accurate & precise results, qualitative detection, error minimization, reducing undesired use of antibiotics and time conservation is expected to upsurge the mononucleosis diagnostic industry over the forecast period.
The overall mononucleosis diagnostic market is categorized on the basis of types of tests available such as monospot Tests, CBC Tests, and Epstein Barr Virus (EBV) antibody tests. Monospot test constituted the largest share of the market as of 2014, owing to factors such as rapid detection of antibody, noninterference with other tests, accurate results, and greater cost-effectiveness. EBV antibody test market is gaining popularity and is expected to gain market share in the future owing to the failure of monospots test and better patient diagnosis.
Geographically, the entire mononucleosis market is segmented into North America, Europe, Asia Pacific, Latin America, and MEA. As of 2014, North America constituted the largest share of the mononucleosis diagnostic market attributing to factors such as advanced healthcare infrastructure supporting novel testing, and increasing incidence rate of epidemics. According to Centres for Disease Control and Prevention (CDC), the majority of people in the United States overall age groups had been infected with Mononucleosis. It has also been stated that nearly half of the children are patients of mononucleosis responsible for the initiation of the disease in the region. However, in Asia Pacific, there is higher incidence of mononucleosis at an early age in comparison to developed regions where incidence takes place during adolescence. Thus, Asia Pacific region is expected to exhibit lucrative growth rate over the forecast period attributing to an increasing prevalence rate of epidemics along with supportive government initiatives for the eradication of diseases, sanitary & living conditions especially in the emerging economies of India and China.
Some key players operating in this market are Daiichi, Digene, Hemagen, Meridian, Gene-Tac, Biotest, Abbott Laboratories, Bio-Rad, Genzyme, Roche, Zenith Johnson & Johnson, Becton Dickinson, Diasorin, Beckman Coulter, Alere. These companies are involved in extensive R&D with a view of increasing market penetration via new product development along with capitalizing the untapped opportunities in the Asia Pacific region. Mergers and acquisitions and partnership agreements are further expected to provide lucrative growth platform to mononucleosis diagnostic market over the forecast period.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.